Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 17, 2019 at 12:12 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

    article source
     

  2. anonymous

    anonymous Guest

    Yes but the data isn’t nearly as good as Bayer’s data